The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer

Sofia Edin1*, Maria L. Wikberg1*, Anna M. Dahlin1, Jörgen Rutegård2, Åke Öberg2, Per-Arne Oldenborg3, Richard Palmqvist1

1 Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden, 2 Department of Surgical and Perioperative Sciences, Surgery, Umeå University, Umeå, Sweden, 3 Department of Integrative Medical Biology, Histology and Cell Biology, Umeå University, Umeå, Sweden

Abstract

High macrophage infiltration has been correlated to improved survival in colorectal cancer (CRC). Tumor associated macrophages (TAMs) play complex roles in tumorigenesis since they are believed to hold both tumor preventing (M1 macrophages) and tumor promoting (M2 macrophages) activities. Here we have applied an immunohistochemical approach to determine the degree of infiltrating macrophages with a M1 or M2 phenotype in clinical specimens of CRC in relation to prognosis, both in CRC in general but also in subgroups of CRC defined by microsatellite instability (MSI) screening status and the CpG island methylator phenotype (CIMP). A total of 485 consecutive CRC specimens were stained for nitric oxide synthase 2 (NOS2) (also denoted iNOS) as a marker for the M1 macrophage phenotype and the scavenger receptor CD163 as a marker for the M2 macrophage phenotype. The average infiltration of NOS2 and CD163 expressing macrophages along the invasive tumor front was semi-quantitatively evaluated using a four-graded scale. Two subtypes of macrophages, displaying M1 (NOS2+) or M2 (CD163+) phenotypes, were recognized. We observed a significant correlation between the amount of NOS2+ and CD163+ cells (P<0.0001). A strong inverse correlation to tumor stage was found for both NOS2 (P<0.0001) and CD163 (P<0.0001) infiltration. Furthermore, patients harbouring tumors highly infiltrated by NOS2+ cells had a significantly better prognosis than those infiltrated by few NOS2+ cells, and this was found to be independent of MSI screening status and CIMP status. No significant difference was found on cancer-specific survival in groups of CRC with different NOS2/CD163 ratios. In conclusion, an increased infiltration of macrophages with a M1 phenotype at the tumor front is accompanied by a concomitant increase in macrophages with a M2 phenotype, and in a stage dependent manner correlated to a better prognosis in patients with CRC.

Introduction

Inflammatory cells are present in the tumor microenvironment of most cancers and have been reported to affect the milieu of inflammatory mediators and cell proliferation signals, angiogenesis and tissue remodelling in ways that could promote tumor progression [1–3]. Tumor-associated macrophages (TAMs) and their roles in tumor invasion and metastasis have been discussed in several recent reviews [4–8]. In general, TAMs are found within and surrounding most tumors and can, when activated, release numerous factors that could influence the behaviour of tumor cells and other cells of tumor stroma. The ability of macrophages to adapt to their environment has lead to the identification of two main polarized phenotypes of macrophages [7,9]. In brief, the classically activated M1 macrophages are characterized by the expression of nitric oxide synthase 2 (NOS2) (also denoted iNOS), as well as many pro-inflammatory cytokines (e.g IL1β, IL6, IL12, IL23 and TNF) and are reported to have a high bactericidal and tumoricidal capacity. The main functions of the alternatively activated M2 macrophages are instead to scavenge debris and promote tissue repair, but they also have immune regulatory functions. Many of the factors produced by M2 macrophages act in favour of tumor progression, stimulating tumor growth, (e.g. epidermal growth factor (EGF), fibroblast growth factor 1 (FGF1) and transforming growth factor beta 1 (TGFβ1), angiogenesis (e.g. vascular endothelial growth factor A (VEGFA) and matrix remodelling (e.g. FGF1, fibrin and matrix metallopeptidases (MMPs)). In addition, M2 macrophages also produce immune regulatory factors (e.g. IL10 and TGFβ1) that dampen the immune response.

TAMs are often found to have a M2 phenotype and have been associated with a decreased survival in patients with e.g. melanoma [10,11], breast [12,13], kidney [14] and bladder cancer.
[15,16]. However, this is not true for all cancers. We and others have previously shown that an increased density of macrophages in CRC is correlated to a better prognosis [17–20]. Also stomach cancer patients have been reported to have a better prognosis with a high number of TAMs [21,23]. The results on prostate [23,24], lung [25–29] and endometrial cancer [30–32] are however conflicting. It is becoming increasingly evident that macrophages can play different roles in tumorigenesis dependent on tissue and cancer type. It is interesting to speculate that the different roles played by macrophages in various cancers could involve variations in the balance between M1 and M2 phenotypes (tumor prevention vs. tumor promotion), driven by factors in the tumor microenvironment of individual cancers. There could also be variations within certain cancer types.

CRCs have been subtyped according to their microsatellite (MSI) status and the CpG island methylator phenotype (CIMP). Approximately 15% of CRCs are defined as microsatellite unstable (MSI), a phenotype caused by defects in DNA mismatch repair, which is in contrast to microsatellite stable (MSS) CRCs [33]. In sporadic CRCs, MSI has been highly associated with CIMP [34]. CIMP can be classified as CIMP-high or CIMP-low according to the hypermethylation status of CpG islands in a set of genes that are unmethylated in normal colorectal tissue or in CIMP-negative tumors [35–38].

In the present study, the distribution of different subtypes of macrophages was evaluated in 485 clinical specimens of CRC, using nitric oxide synthase 2 (NOS2) as a marker for the M1 macrophage phenotype and the scavenger receptor CD163 as a marker for the M2 macrophage phenotype. The infiltration of NOS2+ and CD163+ cells was related to clinicopathologic and molecular variables, as well as prognosis, both in the complete CRC cohort and in subgroups of CRC defined by MSI screening status and CIMP status. We could conclude that infiltration of M1 macrophages in CRC is accompanied by infiltrating M2 macrophages and correlated to improved survival in a stage dependent manner in CRC, and that this is independent of MSI screening status and CIMP status.

**Materials and Methods**

**Ethics Statement**

The handling of tissue samples and patient data in the present study was approved by the research ethical committee at Umeå University Hospital (Regional Ethical Review Board in Umeå, Sweden), including the procedure whereby patients verbally gave their informed consent. This consent was documented in each patient record, and considered by the Ethics Committee to be sufficient. Tissue samples were registered as a case number and year in a database used for the analyses, with no names or personal identification number indicated.

**Study population**

Clinical specimens from patients of the Colorectal Cancer in Umeå Study (CRUMS) [39], surgically resected for CRC were collected between 1993 and 2003 at the department of Surgery, Umeå University Hospital, Umeå, Sweden. From all patients, formalin-fixed paraffin embedded tissue was sampled and pathological variables were characterized by one pathologist by reviewing routinely stained sections. Clinical data, including survival data, were obtained by one surgeon by reviewing the patient records. A total of 485 patients (300 colon cancers, 180 rectal cancers, and 5 not specified subsite within the colorectum) were included in the study. With 28 patients missing information on either NOS2 or CD163 expression, 474 specimens for NOS2 and 468 specimens for CD163 were available for analysis. Adjuvant chemotherapy was administered to 68 (14.0%) patients. Preoperative radiation therapy was administered to 108 (60.0%) rectal cancer patients of whom 83 received 5 Gy, and 25 received 25 Gy. For survival analyses, 37 patients were excluded due to incomplete follow-up data or due to death by perioperative complications. For survival analyses scores regarding the NOS2/CD163 ratio, a total of 422 patients were available.

**Immunohistochemistry and immunofluorescence**

Specimens were fixed in 4% formaldehyde and embedded in paraffin, according to routine procedures at the department of Clinical Pathology, Umeå University Hospital, Umeå Sweden. One 4-µm section from each patient was cut, dried, de-waxed and rehydrated. Slides were then subjected to heat-mediated antigen retrieval using Dviva solution (Biocare Medical, Concord, CA) in a Decloaker™ pressure cooker. For immunohistochemical procedures, a semiautomatic staining machine (Ventana ES, Ventana Inc., Tuscon, AZ) was used. Anti-CD163 monoclonal antibody (Novoceastra) was used at a dilution of 1:100, and anti-NOS2 polyclonal antibody (Abcam) was used at a dilution of 1:50. The slides were counterstained with haematoxylin.

For evaluation, slides were reviewed under light microscope. Immunohistochemical staining was evaluated as most representative area at the invasive front and assessed as no/weak (score 1), moderate (score 2), strong/robust (score 3) and massive infiltration (score 4) according to Forsell et al. [18]. The specimens were evaluated two times by the same observer, and discordant cases were reviewed a third time, followed by a conclusive judgement. For immunofluorescense, anti-CD163 monoclonal antibody, anti-NOS2 rabbit polyclonal antibody and anti-CD68 rabbit polyclonal antibody (GeneFex Inc) was used at a dilution of 1:50, and anti-CD68 mouse monoclonal antibody (Dako) was used at a dilution of 1:400. For block, the tissue sections were treated with PBS containing 10% normal goat serum and 0.4% Triton X-100. For survival analyses, 37 patients were excluded due to incomplete follow-up data or due to death by perioperative complications. For survival analyses scores regarding the NOS2/CD163 ratio, a total of 422 patients were available.

**MSI screening status and CIMP status**

MSI screening status was determined by immunohistochemistry as previously described [39]. A positive MSI screening status (MSI) was assigned to tissue samples with tumor cells lacking nuclear staining for one or more of the proteins MLH1, MSH2, MSH6, or PMS2, this in contrast to a negative screening status (MSS), where positive tumor nuclei were present expressing all four markers. CIMP status was determined according to hypermethylation of an eight-gene panel (CDKN2A, MLH1, AGAAT1, NEUROG1, RUNX3, SOCS1, IGF2, and CRABP1) by the MethyLight method (quantitative real-time PCR) with previously described primer and probe sequences [39,40]. The following number of hypermethylated genes defined CIMP-negative tumors, 0 genes; CIMP-low tumors, 1–5 genes; and CIMP high tumors, 6–8 genes.
Statistical analyses

Statistical analyses were performed using PASW Statistics 18 (SPSS Inc., Chicago, Illinois, USA). Cross-tabulations were analyzed with Fisher’s exact test and linear relationships with the exact linear-by-linear association test. Kaplan-Meier survival analysis was used to estimate cancer-specific survival, and comparisons between groups were performed with the log-rank test. Cancer-specific survival was defined as death with known disseminated or recurrent disease. Multivariate survival analyses were performed by using Cox proportional hazard models. \( P < 0.05 \) was considered statistically significant.

Results

Expression of M1 and M2 macrophage markers

NOS2 was selected as a marker for macrophages with a M1 phenotype and CD163 as a marker for macrophages with a M2 phenotype. To validate whether NOS2 and CD163 were markers, able to separate between distinct populations of macrophages, specimens of 10 CRC patients were randomly selected and the distribution of NOS2 and CD163 was analyzed by double immunofluorescent staining followed by confocal microscopy. NOS2 and CD163 was found to be primarily expressed by different populations of macrophages (Figure 1A). A small overlap could however be identified, which is in line with the plastic nature of macrophages. Macrophages that highly expressed one of the markers, however, consistently did not express the second marker. This verifies NOS2 and CD163 as markers that can be used to distinguish between different subpopulations of macrophages displaying mainly M1 or M2 phenotypes, respectively. Furthermore, NOS2 and CD163 expression was found in cells that also expressed the macrophage marker CD68 (Figure 1B and C).

Expression of NOS2 and CD163 was semi-quantitatively evaluated in specimens from 485 CRC patients using immunohistochemistry according to a previously documented four-graded scale [18]. Representative stainings of infiltrating NOS2\(^+\) or CD163\(^+\) macrophages are shown in Figure 2. Approximately 70\% of all tumors displayed a modest to massive infiltration of NOS2\(^+\) and CD163\(^+\) cells (score 2–4); while the remaining showed weak or no infiltration (score 1). The majority of NOS2 and CD163 expression was found in cells located in the tumor stroma, with the highest density along the invasive tumor front.

The relationship between NOS2\(^+\) and CD163\(^+\) macrophages

The frequencies of infiltrating NOS2\(^+\) and CD163\(^+\) macrophages at the tumor front are presented in Table 1. Infiltrating macrophages expressing NOS2 or CD163 were highly positively correlated (\( P = 0.0001 \)). The amounts of CD163\(^+\) cells at the tumor front, however, were frequently higher than that of NOS2\(^+\) cells.

Association between infiltrating NOS2\(^+\) and CD163\(^+\) macrophages and clinicopathologic and molecular parameters

The scores of infiltrating NOS2\(^+\) and CD163\(^+\) macrophages in CRC specimens were correlated to various clinicopathologic variables (Table 2). When including all tumors, no relation of NOS2\(^+\) or CD163\(^+\) macrophage infiltration was found to gender, age, grade, growth pattern, adjuvant chemotherapy or preoperative radiotherapy. A weak linear trend was found for increased infiltration of NOS2\(^+\) macrophages from the caecum to the rectum (\( P = 0.043 \)). While no significant association of NOS2 expression was found with tumor type, a significant association with tumor type was found for CD163 expression (\( P = 0.005 \)), with CD163 infiltrated tumors more often having a non-mucinous histology. A strong inverse association with tumor stage was found for both NOS2\(^+\) (\( P < 0.0001 \)) and CD163\(^+\) (\( P < 0.0001 \)) macrophage infiltration.

When relating infiltrating NOS2\(^+\) or CD163\(^+\) macrophages to molecular parameters (Table 3), no correlation of NOS2\(^+\) or CD163\(^+\) macrophage infiltration was found to either MSI screening status or CIMP status. When combining MSI screening status with CIMP status however, CD163\(^+\) macrophage infiltration was found to be significantly lower in CIMP-high tumors compared with CIMP-negative or CIMP-low tumors among the group of MSS tumors (\( P = 0.042 \)).

Prognostic importance of infiltrating NOS2\(^+\) and CD163\(^+\) macrophages

To assess the prognostic impact of macrophage infiltration, we compared overall cancer-specific survival in patients with different scores of infiltrating NOS2\(^+\) or CD163\(^+\) macrophages. Figure 3 shows Kaplan-Meier plots of cancer-specific survival in CRUMS patients with different levels of infiltrating NOS2\(^+\) and CD163\(^+\) macrophages. An increased infiltration of NOS2\(^+\) macrophages at the tumor front was highly significantly associated with an improved prognosis (Log-rank \( P = 0.0003 \)) (Figure 3A). A similar association was seen also for CD163\(^+\) macrophages (Log-rank \( P < 0.0001 \)) (Figure 3D). In potentially curatively resected CRCs (i.e., excluding patients with distant metastases or non-radical surgery) the significance of the association between NOS2\(^+\) macrophage infiltration and prognosis was lost (Log-rank \( P = 0.132 \)). However, in this group the significance of NOS2\(^+\) macrophage infiltration and prognosis was restored when separating cases of colon cancer from rectal cancers, Log-rank \( P = 0.008 \) in colon compared to Log-rank \( P = 0.881 \) in rectum (Figure 3B and C). For the corresponding analysis of CD163\(^+\) macrophage infiltration in curatively resected CRCs a similar tendency was found (Log-rank \( P = 0.034 \) in all CRCs; Log-rank \( P = 0.059 \) in colon; Log-rank \( P = 0.236 \) in rectum) (Figure 3E and F).

Because of the strong correlation between tumor stage and the expression of NOS2 and CD163 we performed multivariate Cox proportional hazard models including the variables gender, age, localization, tumor stage, and one macrophage marker, respectively. Hazard ratios (HRs) for both NOS2 (HR 0.67, 95% CI 0.40–1.12, \( P = 0.12 \)) and CD163 (HR 0.66, 95% CI 0.42–1.06, \( P = 0.087 \)) indicated a protective effect but did not reach statistical significance, emphasizing the stage dependence.

The possible effect of variations in NOS2/CD163 ratio on patient survival was also analyzed. No significant difference was seen on cancer-specific survival in CRC in relation to the NOS2/CD163 ratio, neither in all CRC cases (Figure 4A) nor in the selected group of potentially curatively resected colon cancers (Figure 4B). Furthermore, the NOS2/CD163 ratio was not significantly associated with survival in multivariate analysis (data not shown).

Prognostic importance of infiltrating NOS2\(^+\) and CD163\(^+\) macrophages according to MSI screening status and CIMP status

To further analyze the prognostic value of macrophage infiltration, we compared overall cancer-specific survival within different subgroups of CRC defined by MSI screening status and CIMP status.
MSI cases of CRC are found to have a slightly better prognosis compared to MSS cases [33]. Macrophage infiltration was found to be a prognostic factor in subgroups of both MSI (Figure 5A and D) and MSS cases (Figure 5B and E). The prognostic value of NOS2+ macrophage infiltration did not reach significance in MSI cases (Log-rank $P = 0.256$), but it did so in MSS cases (Log-rank $P = 0.002$). CD163+ macrophage infiltration was significant for prognosis in both MSI (Log-rank $P = 0.009$) and MSS (Log-rank $P = 0.003$) cases. When combining MSI screening status with low (score 1–2) or high (score 3–4) infiltration of NOS2+ or CD163+ macrophages, significant effects on prognosis was found for both NOS2+ (Log-rank $P = 0.005$) and CD163+ (Log-rank $P = 0.0004$) macrophage infiltration (Figure 5C and F). The most favourable prognosis was found in MSI cases highly infiltrated by macrophages, in particular by NOS2+ macrophages. MSS cases with low macrophage infiltration displayed the worst prognosis (Figure 5C and F). No significant differences on prognosis were found between MSI and MSS cases within subgroups with low or high infiltration of NOS2+ or CD163+ macrophages.

Macrophage infiltration was shown to be of prognostic importance in all CIMP subgroups (Figure 6A–C and E–G). NOS2+ macrophage infiltration showed a significant effect on

![Figure 1. NOS2 and CD163 distinguish between different macrophage phenotypes.](image1)

![Figure 2. NOS2 and CD163 immunoreactivity in patient samples.](image2)

### Table 1. Cross-tabulation between NOS2 and CD163.

| CD163 | 1   | 2   | 3   | 4   | $P$       |
|-------|-----|-----|-----|-----|-----------|
| 1     | 79  | 51  | 3   | 0   | <$0.0001^*$|
| 2     | 64  | 105 | 28  | 14  | 0         |
| 3     | 10  | 52  | 47  | 4   | 3.5       |
| 4     | 4   | 28  | 50  | 7   | 21.4      |

*DExact linear-by-linear association test.

*Source: doi:10.1371/journal.pone.0047045.g000

*Source: doi:10.1371/journal.pone.0047045.g002

*Source: doi:10.1371/journal.pone.0047045.t001

The most favourable prognosis was found in MSI cases highly infiltrated by macrophages, in particular by NOS2+ macrophages. MSS cases with low macrophage infiltration displayed the worst prognosis (Figure 5C and F). No significant differences on prognosis were found between MSI and MSS cases within subgroups with low or high infiltration of NOS2+ or CD163+ macrophages.
cancer-specific survival in CIMP-low cases (P = 0.011). Macrophages expressing CD163 showed significant effects on prognosis in CIMP-neg (Log-rank P = 0.006) and CIMP-high (Log-rank P = 0.022) cases. When combining CIMP screening status with low (score 1–2) or high (score 3–4) infiltration of macrophages expressing NOS2 or CD163, significant effects on prognosis was found for both NOS2 (Log-rank P = 0.015) and CD163 (Log-rank P = 0.001) infiltration (Figure 6D and H). The most favourable prognosis was found in highly infiltrated CIMP subgroups (Figure 6D and H). CIMP subgroups with low infiltration of NOS2* or CD163* cells in comparison showed a worse prognosis. No significant differences on prognosis were found between CIMP-negative, CIMP-low or CIMP-high cases within subgroups with low or high infiltration of NOS2* or CD163* macrophages.

### Table 2. NOS2 and CD163 expression at the tumor invasive front in relation to clinicopathologic characteristics in CRC.

|                | NOS2        | CD163       |
|----------------|-------------|-------------|
|                | 1 2 3 4     | 1 2 3 4     |
| **Frequency (%)** |            |             |
| 158 (33.3)     | 221 (46.6)  | 86 (18.1)   |
| 138 (29.5)     | 202 (43.2)  | 114 (24.4)  |
| **Gender, n (%)** | 0.543      | 0.479       |
| Male           | 80 (30.5)   | 128 (48.9)  |
| Female         | 78 (36.8)   | 93 (43.9)   |
| **Age, n (%)** | 0.087/0.378* | 0.106/0.651* |
| ≤59            | 24 (26.1)   | 45 (48.9)   |
| 60–69          | 41 (34.7)   | 51 (43.2)   |
| ≥80            | 24 (24.0)   | 56 (56.0)   |
| **Localization, n (%)** | 0.824/0.043* | 0.919/0.279* |
| Caecum         | 16 (32.7)   | 27 (55.1)   |
| Ascending colon| 34 (44.2)   | 28 (36.4)   |
| Transverse colon| 7 (33.3) | 12 (57.1)   |
| Splenic flexure| 5 (33.3)    | 7 (46.7)    |
| Descending colon| 3 (23.1)   | 7 (53.8)    |
| Sigmoid colon  | 41 (34.5)   | 53 (44.5)   |
| Rectum         | 52 (29.5)   | 85 (48.3)   |
| **Stage, n (%)** | 0.002<0.0001* | 0.200<0.001* |
| I              | 17 (23.6)   | 33 (45.8)   |
| II             | 53 (28.3)   | 88 (47.1)   |
| III            | 35 (36.5)   | 48 (50.0)   |
| IV             | 51 (46.8)   | 47 (43.1)   |
| **Grade, n (%)** | 0.301      | 0.227       |
| Low            | 66 (28.8)   | 114 (49.8)  |
| High           | 87 (36.7)   | 106 (44.7)  |
| **Growth pattern, n (%)** | 0.183      | 0.663       |
| Pushing        | 60 (38.7)   | 70 (45.2)   |
| Infiltrating   | 94 (30.4)   | 147 (47.6)  |
| **Histology type, n (%)** | 0.348      | 0.005       |
| Non-mucinous   | 127 (32.0)  | 188 (47.4)  |
| Mucinous       | 29 (41.4)   | 31 (44.3)   |
| **Adjuvant chemotherapy, n (%)** | 0.245      | 0.814       |
| No             | 127 (31.8)  | 192 (48.1)  |
| Yes            | 28 (43.1)   | 25 (38.5)   |
| **Preoperative radiation therapy**, n (%) | 0.326      | 0.941       |
| No             | 23 (32.4)   | 34 (47.9)   |
| Yes            | 29 (27.6)   | 51 (48.6)   |

The following number of missing cases were present in analyses for NOS2 and CD163, respectively: localization, 4 and 5; stage, 10 and 9; grade, 8 and 8; growth pattern, 10 and 9; histology type, 7 and 7; adjuvant chemotherapy, 10 and 11, and preoperative radiation therapy; 4 and 10. Unless otherwise indicated, Fisher’s exact test was used for categorical variables.

*Exact linear-by-linear association test was used to test for linear relationship between variables.

Preoperative radiation therapy in rectal cancers only.

doi:10.1371/journal.pone.0047045.t002
The following number of missing cases were present in analyses for NOS2 and CD163, respectively: MSI screening status, 13 and 15; CIMP status, 2 and 2, and combined MSI screening and CIMP status, 14 and 16. Fisher’s exact test was used for categorical variables.

The number of hypermethylated genes found for CIMP-negative, 0 genes; CIMP-low, 1–5 genes, and CIMP-high, 6–8 genes. MSI, microsatellite instability; MSS, microsatellite stable; CIMP, CpG island methylator phenotype.

doi:10.1371/journal.pone.0047045.t003

### Discussion

The host microenvironment undergoes dramatic changes during the progression of cancer, affecting stromal cells, matrix composition, angiogenesis as well the immune response, which in turn can have significant effects on tumor growth and spread [41]. An inflammatory tumor microenvironment has been suggested to be of the seventh hallmark of cancer progression [42]. Analysis of the immune contexture - i.e. the location, density and functional orientation of immune cells - and how it is integrated with tumor molecular features can provide important information on patient prognosis as well as prediction of the response to various treatment therapies [43,44]. Macrophages play an important role at the tumor front, secreting factors that in many ways might affect both the tumor and surrounding stromal cells, including other cells of the immune system.

We have previously shown in a relatively large clinical cohort that a high infiltration of cells expressing the macrophage marker CD68 at the tumor front in CRC results in an improved prognosis [18]. Here, the distribution of macrophages with a M1 or M2 phenotype was evaluated in situ in this cohort to analyze for the importance of different subtypes of macrophages in CRC patient prognosis. For this study, NOS2 and CD163 were selected as markers to separate between macrophages displaying primarily M1 or M2 phenotypes, respectively. Both NOS2 and CD163 have been utilized by others as markers to define M1 and M2 macrophage populations. However, markers of M1 and M2 macrophages can still be used to recognize the main phenotype or function of different macrophage populations. Even though we find that NOS2 and CD163 are expressed by different populations of macrophages, there is still a risk that not all M1 or M2 macrophages express these markers and that we therefore might lose parts of the macrophage populations in our study. Further studies are needed to verify the M1 and M2 phenotypes and to find more specific markers that distinguish between M1 and M2 macrophage populations.

When correlated to clinicopathologic characteristics (Table 2), a weak linear trend was found for increased infiltration of M1 macrophages from the caecum to the rectum, which is in line with the colorectal continuum theory proposed by Yamauchi et al [59,60]. In their study, CIMP-high, MSI-high and BRAF mutations were found to gradually increase from the rectum to the ascending colon. Cecal cancers were found to represent a unique subtype that did not follow the linearity trend. However, for macrophage infiltration caecal cancers were not excluded from linearity. Expression of NOS2 and CD163 inversely correlated to tumor stage, indicating that higher stage tumors to a larger extent have escaped the immune system. Furthermore, NOS2 and CD163 expression correlated well to expression of the macrophage marker CD68 (P<0.0001), which suggests that NOS2 and CD163 are expressed by cells of the macrophage lineage.

In many clinical studies it has been observed that a high infiltration of TAMs correlates to a poor prognosis and TAMs are thus suggested to be of M2 phenotype that promote tumor progression. However, we and others have recently seen that high

| NOS2 | CD163 |
|------|-------|
| MSI screening status, n (%) | 0.439 | 0.182 |
| MSI | 19 (26.4) | 36 (50.0) | 16 (22.2) | 1 (1.4) | 17 (23.6) | 29 (40.3) | 22 (30.6) | 4 (5.6) |
| MSS | 137 (35.2) | 178 (45.8) | 67 (17.2) | 7 (1.8) | 117 (30.7) | 166 (43.6) | 89 (23.4) | 9 (2.4) |
| CIMP status, n (%) | 0.297 | 0.115 |
| CIMP-negative | 71 (29.8) | 120 (50.4) | 40 (16.8) | 7 (2.9) | 65 (28.0) | 104 (44.8) | 52 (22.4) | 11 (4.7) |
| CIMP-low | 66 (37.7) | 73 (41.7) | 35 (20.0) | 1 (0.6) | 58 (33.0) | 69 (39.2) | 48 (27.3) | 1 (0.6) |
| CIMP-high | 19 (32.2) | 28 (47.5) | 11 (18.6) | 1 (1.7) | 14 (24.1) | 28 (48.3) | 14 (24.1) | 2 (3.4) |
| Combined MSI screening and CIMP status, n (%) | 0.735 | 0.705 |
| MSI CIMP-negative | 2 (13.3) | 10 (66.7) | 3 (20.0) | 0 (0.0) | 5 (33.3) | 6 (40.0) | 3 (20.0) | 1 (6.7) |
| MSI CIMP-low | 6 (33.3) | 9 (50.0) | 3 (16.7) | 0 (0.0) | 5 (27.8) | 5 (27.8) | 7 (38.9) | 1 (5.6) |
| MSI CIMP-high | 11 (28.2) | 17 (43.6) | 10 (25.6) | 1 (2.6) | 7 (17.9) | 18 (46.2) | 12 (30.8) | 2 (5.1) |
| MSS CIMP-negative | 68 (31.1) | 109 (49.8) | 36 (16.4) | 6 (2.7) | 60 (28.2) | 96 (45.1) | 48 (22.5) | 9 (4.2) |
| MSS CIMP-low | 60 (40.0) | 59 (39.3) | 30 (20.0) | 1 (0.7) | 50 (33.3) | 60 (40.0) | 40 (26.7) | 0 (0.0) |
| MSS CIMP-high | 8 (42.1) | 10 (52.6) | 1 (5.3) | 0 (0.0) | 6 (35.3) | 10 (58.8) | 1 (5.9) | 0 (0.0) |

The the number of missing cases were present in analyses for NOS2 and CD163, respectively: MSI screening status, 13 and 15; CIMP status, 2 and 2, and combined MSI screening and CIMP status, 14 and 16. Fisher’s exact test was used for categorical variables.

Cases lacking nuclear staining of tumor cells for at least one of MLH1, MSH2, MSH6, or PMS2 were considered to have a positive MSI screening status.

Phenotype determined according to hypermethylation of an eight-gene panel with the following number of hypermethylated genes found for CIMP-negative, 0 genes; CIMP-low, 1–5 genes, and CIMP-high, 6–8 genes.

The number of missing cases were present in analyses for NOS2 and CD163, respectively: MSI screening status, 13 and 15; CIMP status, 2 and 2, and combined MSI screening and CIMP status, 14 and 16. Fisher’s exact test was used for categorical variables.

Cases lacking nuclear staining of tumor cells for at least one of MLH1, MSH2, MSH6, or PMS2 were considered to have a positive MSI screening status.

Phenotype determined according to hypermethylation of an eight-gene panel with the following number of hypermethylated genes found for CIMP-negative, 0 genes; CIMP-low, 1–5 genes, and CIMP-high, 6–8 genes.
amounts of TAMs in CRC impart a better prognosis and survival rate [17–20, 52]. This is the first study, to our knowledge, where markers for subtypes of M1 and M2 macrophages are used together in purpose to compare the distribution of different macrophage phenotypes and their relation to prognosis in CRC. We could observe a significant statistical correlation between the amount of NOS2+ and CD163+ macrophages (P<0.0001), demonstrating the parallel presence of macrophages with both M1 and M2 phenotypes at the tumor invasive front (Table 1). Furthermore, an increased infiltration of both NOS2+ and CD163+ macrophages at the tumor front was correlated to a significantly improved prognosis (Figure 3). This correlation was

Figure 3. Cancer-specific survival in CRC patients. CRC cases were scored for NOS2 (A–C) and CD163 (D–F) expression, score 1–4. Shown are Kaplan-Meier plots of cancer-specific survival in (A and D) all CRCs, (B and E) potentially curatively resected colon cancers, and (C and F) potentially curatively resected rectal cancers. Log-rank tests were used to calculate P values.
doi:10.1371/journal.pone.0047045.g003
Stabilin-1 et al. found a positive correlation of peritumoral CLEVER-1/however evaluate the parallel presence of M1 macrophages. Algars a significantly improved survival [52]. These authors did not M2 macrophages could be important for patient outcome.

The relation between infiltrating macrophages of M2 phenotype and prognosis in CRC has been previously analyzed in a few studies. According to Nagorsen et al., like in our study, stromal infiltration of CD163\(^+\) M2 macrophages in CRC was correlated to a significantly improved survival [52]. These authors did not however evaluate the parallel presence of M1 macrophages. Algars et al. found a positive correlation of peritumoral CLEVER-1/Stabilin-1\(^+\) M2 macrophages and survival in CRCs [17]. They further found that a low M1/M2 ratio resulted in more recurrent disease. However, in their study M1 macrophages were regarded as those macrophages that did not express Clever-1/Stabilin-1. M1 macrophages have been proposed to have tumoricidal activity, and as expected, patients harbouring tumors with high infiltration of NOS2\(^+\) macrophages were found to have a significantly better prognosis than those with little or no NOS2 infiltration (Figure 3A). Similar to our study, Ohri et al. performed a study on macrophage distribution in non small cell lung cancer (NSCLC) using, among others, NOS2 as a M1 marker, where the presence of NOS2\(^+\) macrophages in tumor islets, but not tumor stroma, was associated with an improved prognosis [54]. Also Ma et al. recently published a study where M1 macrophages in tumor islets, as well as tumor stroma, of NSCLC were associated with a better prognosis [51]. However, in their study, unlike our results, no effect on prognosis was seen by CD163\(^+\) M2 macrophage infiltration, suggesting that in NSCLC, M1 and M2 macrophage infiltration is not correlated to the same extent as in CRC, or that the functions of M2 macrophages may differ between the two cancer forms. This in turn suggests that there are differences in macrophage distribution and function in different types of cancers, which needs to be further evaluated. The concomitant presence of both subtypes of macrophages in CRC suggests that the balance between M1 and M2 macrophages could be important for patient outcome. However, we were unable to find any difference on survival in patients with different ratios of NOS2\(^+\) to CD163\(^+\) macrophages (Figure 4). Therefore, we speculate that as long as macrophages that display a M1 phenotype are present, their anti-tumorigenic properties might dominate over the tumor promoting effect of macrophages of a M2 phenotype, resulting in a favourable prognosis in our study patients. Possible explanations for the beneficial effect of TAMs on prognosis in CRC compared to the negative effect of TAMs in some other cancers, could be either that the M1 macrophage phenotype is more prominent in CRC or that the M2 phenotypes have less hazardous tumor promoting effects. It is interesting to speculate that in CRC, these differences might be attributed to the intestinal environment, where functional adaptations of macrophages are necessary to maintain local tissue homeostasis [62]. Further studies are required to address the sublocalization of macrophage phenotypes in CRC and how the intestinal tumor microenvironment might support a continuous M1 macrophage reaction. This in turn could lead to the identification of factors that can be used to manipulate the tumor microenvironment in favour or a M1 macrophage response and prevention of tumor progression.

In an attempt to study if the distribution of M1 and M2 macrophage phenotypes might be affected by mutations or epigenetic changes, we looked at the distribution in well characterized subtypes of CRC. The association between an increased macrophage infiltration and an improved prognosis was found to be independent of MSI screening status and CIMP status (Figure 5 and 6, respectively). MSI CRCs are shown to have an improved prognosis compared to MSS CRCs [33], a difference that did not reach statistical significance in this study. MSI tumors are defect in DNA mismatch repair and as a result of accumulating mutations, MSI CRCs are therefore suggested to be more immunogenic [63,64]. According to this theory, Bauer et al. recently recognized a significant correlation between CD163-positive macrophage infiltration and MSI screening status in a selected cohort of Lynch syndrome-associated CRCs [65]. Here, we find no evidence for that MSI tumors are more efficiently recruiting macrophages of either M1 or M2 phenotype compared to MSS tumors (Table 3). Furthermore, we found that macrophage infiltration was of prognostic impact in both MSI and MSS cases (Figure 5). The reason why there are differences between

![Figure 4. NOS2/CD163 ratios and cancer-specific survival in CRC. Cancer-specific survival of CRC cases scored for the NOS2/CD163 ratio. Shown are Kaplan-Meier plots of the NOS2/CD163 ratio in (A) all CRCs, or (B) potentially curatively resected colon cancers. Log-rank tests were used to calculate P values. doi:10.1371/journal.pone.0047045.g004](image)
their study and ours can be explained by the selection for a high level of microsatellite instability (MSI-H) in Lynch syndrome CRCs. However, we did find significant correlations when combining MSI screening status with NOS2 or CD163 macrophage infiltration, suggesting that MSI screening status and macrophage infiltration might be independent prognostic factors (Figure 5).

We found that infiltration of macrophages with a M1 or M2 phenotype is independent of CIMP status (Table 3). When combining MSI screening status and CIMP status, however, a significant correlation was found for CD163 infiltration and CIMP status in MSS CRCs (Table 3). Furthermore, macrophage infiltration was found to have prognostic impact in all CIMP groups (Figure 6). Also here, significant correlations were found.
when combining CIMP status with NOS2a or CD163+ macrophage infiltration (Figure 6).

In conclusion, we show, in line with the general view of M1 and M2 macrophage functions [7,9,58], that high infiltration of M1 macrophages is correlated to a better prognosis in CRC in a stage-dependent manner. However, in CRC the increased infiltration of M1 macrophages at the tumor front was found to be accompanied by a concomitant increase in M2 macrophages. We therefore suggest that the presence of M1 macrophages is favourable for survival in patients with CRC, despite the parallel presence of M2 macrophages.

Acknowledgments

The authors are grateful to Kerstin Näslund for expert technical assistance and all persons who have in any way been involved in CRUMS.

Author Contributions

Conceived and designed the experiments: SE MLW PAO RP. Performed the experiments: SE MLW AMD AOJR RP. Analyzed the data: SE MLW RP. Contributed reagents/materials/analysis tools: SE MLW PAO RP. Wrote the paper: SE MLW AMD AOJR RP.

References

1. Mantovani A, Allavena P, Sica A, Balkwill F (2000) Cancer-related inflammation. Nature 434: 436–444.
2. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, et al. (2009) Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214: 761–777.
3. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P (2010) Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 29: 243–248.
4. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 315–322.
5. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 91–99.
6. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717–727.
7. Sveen KS, Kuttan G (2009) Role of macrophages in tumour progression. Immunol Lett 123: 97–102.
8. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86: 1065–1073.
9. Jenum TO, Schmidt H, Moller HJ, Hoyer M, Maierck MB, et al. (2008) Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage II/III melanoma. J Clin Oncol 26: 204–215.
10. Sica A, Schioppa T, Mantovani A, Allavena P (2006) Tumour-associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717–727.
11. Makitie T, Summanen P, Tarkkanen A, Kivela T (2001) Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalm Vis Sci 42: 1411–1421.
12. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, et al. (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625–4629.
13. Tsutsumi S, Yasuda K, Suzuki K, Tahara K, Higashi H, et al. (2005) Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep 14: 425–431.
14. Hamada I, Kato M, Yamasaki T, Iwahashi K, Watanabe T, et al. (2002) Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res 22: 4281–4284.
15. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, et al. (2009) Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 17: 263–269.
16. Chai CY, Chen WT, Hung WC, Kang WY, Huang YC, et al. (2008) Hypoxia-inducible factor-alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavorable prognosis in urothelial carcinoma. J Clin Pathol 61: 658–664.
17. Algaras A, Iriaza H, Vaittinen S, Huhtinen H, Sundström J, et al. (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131: 864–873.
18. Forssell J, Oberg U, Henriksson ML, Stenling R, Jung A, et al. (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13: 1472–1479.
19. Lackner C, Jukic Z, Tsvyshovskiy O, Jatzko G, Wette V, et al. (2004) Prognostic relevance of tumor-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 445: 160–167.
20. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, et al. (2010) The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 8: 13.
21. Haas M, Dimmler A, Hohenberger W, Grabenhauer GG, Niedobitek G, et al. (2009) Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 9: 65.
22. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, et al. (2003) The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 23: 5013–5022.
23. Lasbriant IF, Statin P, Wikstrom P, Damber JE, Egevad L, et al. (2000) Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17: 445–451.
24. Shimura S, Yang G, Ebata S, Wheeler TM, Frølv A, et al. (2000) Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60: 5037–5061.
25. Chen J, Liu YC, Yao PL, Yuan A, Chen HY, et al. (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 9554–9564.
26. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, et al. (2008) High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer 98: 1138–1144.
27. Takamani I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57: 138–142.
28. Welch TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, et al. (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 23: 8959–8967.
29. Dai F, Liu L, Che G, Yu N, Pu Q, et al. (2010) The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer 10: 229.
30. Hashimoto I, Kodama J, Seki N, Hongo A, Miyagi Y, et al. (2000) Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res 20: 4853–4856.
31. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, et al. (2004) Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 24: 3335–3342.
32. Salvesen HB, Aklen LA (1999) Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 84: 538–543.
33. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609–618.
34. Hawkins N, Norris M, Chong K, Mokony E, Ku SL, et al. (2002) CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122: 1376–1387.
35. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, et al. (2007) Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104: 18654–18659.
36. Toyota M, Ahsa O, Ohe-Toyota M, Herman JG, Baylin SR, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8601–8606.
37. Kambara T, Simmons LA, Whitall VL, Spring KJ, Wynner CV, et al. (2004) BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53: 1137–1144.
38. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8: 582–588.
39. Dahlén AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklöf V, et al. (2010) The role of the CpG island methylator phenotype in colorectal cancer prognosis.
depends on microsatellite instability screening status. Clin Cancer Res 16: 1845–1855.

40. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 39: 787–793.

41. Allen M, Louise Jones J (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223: 162–176.

42. Colotta F, Alleva P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073–1081.

43. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306.

44. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Macrophage Subtypes in Colorectal Cancer. PLoS ONE 6: e22567.

45. Caillou B, Talbot M, Weill M, Arnaud-Durieu C, Al Ghuzlan A, et al. (2011) Tumor-infiltrating macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 52: 643–650.

46. Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al Ghuzlan A, et al. (2011) Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma. PLoS One 6: e22567.

47. Hasita H, Komohara Y, Okabe H, Masuda T, Ohsaka K, et al. (2010) Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 102: 1424–1431.

48. Komohara Y, Hasita H, Ohsaka K, Fujiwara Y, Suzuki S, et al. (2011) Macrophages and their role in growth of human gliomas. J Pathol 224: 15–24.

49. Kurahara H, Shinchi H, Matakai Y, Maemura K, Nozaka H, et al. (2011) Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer. J Surg Res 15: 162722: e211–9.

50. Nagorsen D, Komohara Y, Murayama T, Aoki R, Kimura Y, et al. (2010) Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 60: 278–283.

51. Ohtani CM, Shikata A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour stromas are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33: 118–126.

52. Panzer J, Hesinkkend M, Van der Staaijen T, Jordanova ES, Baak-Pablo R, et al. (2011) Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res 17: 1668–1673.

53. Shabo I, Stal O, Olsson H, Dore S, Svarvik J (2008) Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 125: 780–786.

54. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn H, Walburg KV, et al. (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4): 899–909.

55. Yamauchi M, Lochhead P, Morikawa T, Huttonhower C, Chan AT, et al. (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61: 794–797.

56. Yamauchi M, Morikawa T, Kuchiba A, Inamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectal. Gut 61: 847–854.

57. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn H, Walburg KV, et al. (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4): 899–909.

58. Moser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969.

59. Yamauchi M, Kocher H, Morikawa T, Huttonhower C, Chan AT, et al. (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61: 794–797.

60. Yamauchi M, Morikawa T, Kuchiba A, Inamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectal. Gut 61: 847–854.

61. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Herman J, et al. (2002) Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol 197: 20–27.

62. Weber B, Saurer L, Mueller C (2009) Intestinal macrophages: differentiation and involvement in intestinal immunopathologies. Semin Immunopathol 31: 171–184.

63. Kloor M, Michel S, von Knebel Doeberitz M (2010) Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 127: 1001–1010.

64. Bauer K, Michel S, Reuschenbach M, Nelius N, von Knebel Doeberitz M, et al. (2011) Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam Cancer 10(3): 557–63.